Stephen Fry - Eli Lilly President
| LLY Stock | EUR 708.10 0.60 0.08% |
President
Mr. Stephen F. Fry is Senior Vice President Human Resources and Diversity of the Company. He was the managing director of Lilly Australian affiliate from 2004 2007, then served in human resources capacities as executive director for the intercontinental region and Japan until becoming vice president for biomedicines and emerging markets. He joined Lilly in 1987 as a scientific systems analyst in the company former Greenfield, Ind. laboratories, moving into human resources in 1992. He assumed a leadership role when he was selected as the director of human resources for Lilly United Kingdom affiliate in 1998, followed by executive director positions for both Lilly U.S. affiliate and the pharmaceutical operations area. He has a bachelor degree in business from the University of Indianapolis. since 2011.
| Age | 50 |
| Tenure | 13 years |
| Phone | 317 276 2000 |
| Web | https://www.lilly.com |
Eli Lilly Management Efficiency
The company has return on total asset (ROA) of 0.11 % which means that it generated a profit of $0.11 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.6267 %, meaning that it generated $0.6267 on every $100 dollars invested by stockholders. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Robert Daniels | Apple Inc | 56 | |
| John Colglazier | Apple Inc | N/A | |
| Benjamin Fink | Apple Inc | 47 | |
| John Colglazier | Apple Inc | N/A | |
| Robert Gwin | Apple Inc | 54 | |
| James Kleckner | Apple Inc | 57 | |
| Amanda McMillian | Apple Inc | 44 | |
| Robert Gwin | Apple Inc | 54 | |
| Mitchell Ingram | Apple Inc | 55 | |
| Darrell Hollek | Apple Inc | 58 | |
| James Kleckner | Apple Inc | 57 | |
| Ernest Leyendecker | Apple Inc | 55 | |
| Robert Daniels | Apple Inc | 56 | |
| Robin Fielder | Apple Inc | 37 | |
| Mitchell Ingram | Apple Inc | 55 | |
| Robert Reeves | Apple Inc | 59 | |
| Robert Reeves | Apple Inc | 59 | |
| Amanda McMillian | Apple Inc | 44 | |
| Michael Pearl | Apple Inc | 44 | |
| Benjamin Fink | Apple Inc | 47 | |
| Christopher Champion | Apple Inc | 48 | |
Management Performance
| Return On Equity | 0.63 | |||
| Return On Asset | 0.11 |
Eli Lilly Leadership Team
Elected by the shareholders, the Eli Lilly's board of directors comprises two types of representatives: Eli Lilly inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eli. The board's role is to monitor Eli Lilly's management team and ensure that shareholders' interests are well served. Eli Lilly's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eli Lilly's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ellen Marram, Lead Independent Director | ||
| Kathi Seifert, Independent Director | ||
| Ralph Alvarez, Independent Director | ||
| Jamere Jackson, Independent Director | ||
| Joshua Smiley, CFO, Senior Vice President | ||
| Fionnuala Walsh, Senior Vice President - Global Quality | ||
| Juan Luciano, Director | ||
| Alonzo Weems, VP Officer | ||
| Alfonso Zulueta, Senior Vice President and President - Emerging Markets business | ||
| Anat Ashkenazi, VP CFO | ||
| Jeffrey Simmons, Senior Vice President and President - Elanco Animal Health | ||
| John Lechleiter, Chairman of the Board and Presidentident, CEO | ||
| Karen Horn, Independent Director | ||
| Leigh Pusey, Senior Vice President - Corporate Affairs and Communications | ||
| Melissa Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer | ||
| Darren Carroll, Senior Vice President - Corporate Business Development | ||
| William Kaelin, Director | ||
| Jacob Naarden, CEO VP | ||
| Barton Peterson, Senior Vice President - Corporate Affairs and Communications | ||
| Derica Rice, CFO, Executive Vice President - Global Services | ||
| Enrique Conterno, Senior Vice President and President - Lilly Diabetes | ||
| Raul Alvarez, Independent Director | ||
| Marschall Runge, Director | ||
| Michael Harrington, Senior Vice President General Counsel | ||
| David Hoover, Independent Director | ||
| Maria Crowe, President - Manufacturing Operations | ||
| Anat JD, Gen VP | ||
| David Ricks, Senior Vice President and Presidentident - Lilly Bio-Medicines | ||
| Diogo Rau, VP Officer | ||
| Donald Zakrowski, Chief Fin | ||
| Jan Lundberg, Executive Vice President - Science and Technology and Presidentident - Lilly Research Laboratories | ||
| Carolyn Bertozzi, Independent Director | ||
| Erik Fyrwald, Independent Director | ||
| Susan Mahony, Senior Vice President and President - Lilly Oncology | ||
| Jackson Tai, Director | ||
| Michael Eskew, Independent Director | ||
| Martin MIBS, VP Projects | ||
| Katherine Baicker, Independent Director | ||
| Stephen Fry, Senior Vice President - Human Resources and Diversity | ||
| Franklyn Prendergast, Independent Director |
Eli Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eli Lilly a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.63 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 337.36 B | |||
| Shares Outstanding | 952.35 M | |||
| Shares Owned By Insiders | 0.10 % | |||
| Shares Owned By Institutions | 84.35 % | |||
| Price To Earning | 12.38 X | |||
| Price To Book | 34.47 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Eli Lilly in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Eli Lilly's short interest history, or implied volatility extrapolated from Eli Lilly options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |